<DOC>
	<DOCNO>NCT00230542</DOCNO>
	<brief_summary>The purpose study determine effect ( good bad ) combination carboplatin pemetrexed patient recurrent ovarian , peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Carboplatin Pemetrexed Recurrent Platinum Sensitive Ovarian Cancer</brief_title>
	<detailed_description>- Before patient receive chemotherapy treatment give three medication prevent side effect chemotherapy drug . These medication vitamin B12 , folic acid dexamethasone . - Chemotherapy treatment give intravenously outpatient clinic . Pemetrexed give first take 10 minute infuse follow carboplatin take 30-45 minute infuse . These treatment repeat every three week 6 cycle chemotherapy ( 18 week ) . - Before chemotherapy treatment follow test procedure perform : physical exam medical history ; evaluation ability undertake daily activity ; blood test . - After every 2 cycle chemotherapy ( every 6 week ) patient CT MRI scan measure well cancer respond treatment . - The study treatment last 6 cycle chemotherapy long tumor grow patient n't experience severe side effect .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis platinumsensitive recurrence epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer The follow histologic subtypes eligible : papillary serous , endometrioid , mucinous , clear cell , adenocarcinoma , transitional , mixture . At least one measurable lesion accord RECIST criterion via CT MRI scan Received platinumcontaining regimen initial diagnosis ECOG performance status 0,1 2 18 year age old Life expectancy great 12 week WBC &gt; 1,500/mm3 Neutrophils &gt; 1,500/mm3 Platelets &gt; 100,000/mm3 Total Bilirubin &lt; 1.5 ULN Calculated creatinine clearance &gt; 45 ml/min ALT/AST &lt; 3 x ULN ( liver mets ) ALT/AST &lt; 5 x ULN ( liver mets ) Complete recovery completion previous chemotherapy biologic therapy Negative pregnancy test agree practice effective method birth control Patients sarcomatous , stromal , germ cell element Prior pelvic radiotherapy &gt; 25 % bone marrow Uncontrolled medical problem opinion investigator would preclude safe administration study drug Past history bone marrow transplantation stem cell support Known history CNS metastasis unless patient treatment surgery radiation therapy , neurologically stable , require oral intravenous corticosteroid anticonvulsant Prior malignancy except adequately treat carcinoma situ uterine cervix , incidental stage I endometrial cancer , basal cell squamous cell skin cancer breast cancer ( invasive ductal carcinoma situ ) patient diseasefree least five year Routine prophylactic use GCSF GMCSF blood transfusion within 2 week Clinically significant cardiac disease define : history unstable angina within 6 month ; history symptomatic ventricular arrhythmia ; history congestive heart failure ; history myocardial infarction within 6 month Uncontrolled hypercalcemia diabetes mellitus Any sign intestinal obstruction bowel function and/or nutrition Grade 2 great peripheral neuropathy Participation investigational study within three week History anaphylactic shock prior platinum chemotherapy History psychiatric disability central nervous system disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>platinum-sensitive recurrence</keyword>
	<keyword>carboplatin</keyword>
	<keyword>pemetrexed</keyword>
</DOC>